Plaque Psoriasis

Research finds potential benefits to using apremilast for plaque psoriasis patients.

The results of two phase 3 clinical trials suggest a topical psoriasis treatment option.

The daily TYK2 inhibitor agent was associated with improved rates of psoriasis surface improvement versus apremilast in clinical trials.

Recent research from the National Psoriasis Foundation (NPF) found that 1 in 3 individuals living with psoriatic conditions experience depression.

The latest indications for the novel selective antibody will make it available as a treatment for pustular psoriasis.

Experts in plaque psoriasis discuss the future for the management of plaque psoriasis.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, discuss how clinical trials play an important role in the management of plaque psoriasis.

Dr Jerry Bagel and physician assistant Alexa Hetzel comment on the impact of COVID-19 pandemic on patients with plaque psoriasis.

Experts in plaque psoriasis discuss the impact of access to medication for plaque psoriasis and how biosimilars might impact the treatment of plaque psoriasis.

Jerry Bagel, MD, MS, discusses the relationship between a physician and physician assistant treating plaque psoriasis.

Among flares identified in outpatient (53%), inpatient (36%), and emergency department (9%) settings, the most utilized treatments were topical corticosteroids (35%), opioids (21%), and other oral treatments.

Experts in plaque psoriasis discuss how patients are referred to them for treatment.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, touch on unmet needs that remain in the treatment of plaque psoriasis.

Dr Jerry Bagel and physician assistant Alexa Hetzel comment on other agents available for the treatment of plaque psoriasis.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, discuss the safety and efficacy of deucravacitinib in patients with plaque psoriasis.

The pivotal DERMIS trial author discusses extended assessment and prescribing strategies for the latest psoriasis agent.

A retrospective analysis suggests there are significant disparities in dermatologist visit duration based on patient race and ethnicity.

Dermatologist Raj Chovatiya, MD, PhD, discusses practical use of the newest topical therapy approved by the FDA.

The indication to Arcutis makes the once-daily topical cream the first marketed PDE4 inhibitor of its kind.

Panelists talk about when they might consider switching biologics for patients with plaque psoriasis.

Experts in plaque psoriasis discuss how to select a biologic based on patient factors and comorbidities.

Jerry Bagel, MD, MS, and Alexa Hetzel, MS, PA-C, discuss their experiences with biologics used to treat plaque psoriasis.

Jerry Bagel, MD, MS, discusses the mechanism of action of biologics used in plaque psoriasis.

In the study, 77% of patients treated with the Cal/BD foam treatment were satisfied with its effectiveness, 60% were satisfied with its ease of use, and 73.9% were satisfied in terms of global satisfaction.

Dr. Jerry Bagel and physician assistant, Alexa Hetzel, comment on the burden of plaque psoriasis and what options are available for the treatment of plaque psoriasis.